Logo-bi
Bioimpacts. 2016;6(4): 225-248. doi: 10.15171/bi.2016.30
PMID: 28265539        PMCID: PMC5326671

Review

Blood-brain barrier transport machineries and targeted therapy of brain diseases

Jaleh Barar 1,2 ORCID, Mohammad A. Rafi 3, Mohammad M. Pourseif 1, Yadollah Omidi 1,2 * ORCID

Cited by CrossRef: 182

1- Belykh E, Shaffer K, Lin C, Byvaltsev V, Preul M, Chen L. Blood-Brain Barrier, Blood-Brain Tumor Barrier, and Fluorescence-Guided Neurosurgical Oncology: Delivering Optical Labels to Brain Tumors. Front Oncol. 2020;10 [Crossref]
2- Kurtulmuş A, Koçana C, Toprak S, Sözer S. The role of Extracellular Genomic Materials (EGMs) in psychiatric disorders. Transl Psychiatry. 2023;13(1) [Crossref]
3- Henrio Marcellin D, Huang J. Exploring Zika Virus Impact on Endothelial Permeability: Insights into Transcytosis Mechanisms and Vascular Leakage. Viruses. 2024;16(4):629 [Crossref]
4- Khan I, Baig M, Mahfooz S, Imran M, Khan M, Dong J, Cho J, Hatiboglu M. Nanomedicine for glioblastoma: Progress and future prospects. Seminars in Cancer Biology. 2022;86:172 [Crossref]
5- Gyawali A, Kang Y. Pretreatment Effect of Inflammatory Stimuli and Characteristics of Tryptophan Transport on Brain Capillary Endothelial (TR-BBB) and Motor Neuron Like (NSC-34) Cell Lines. Biomedicines. 2020;9(1):9 [Crossref]
6- Sharma N, Arora V, Joshi G, Prajapati B, Parihar A. Role of nanoparticles in pancreatic drug delivery: Including a bibliography on Targeted drug delivery. IJCAAP. 2023;8(2):112 [Crossref]
7- Dunn J, Isaacs A. The impact of hypoxia on blood-brain, blood-CSF, and CSF-brain barriers. Journal of Applied Physiology. 2021;131(3):977 [Crossref]
8- Chen J, Tian C, Xiong X, Yang Y, Zhang J. Extracellular vesicles: new horizons in neurodegeneration. eBioMedicine. 2025;113:105605 [Crossref]
9- Sureshkumar M, Pandian A. Accessing the Blood-Brain Barrier to Treat Brain Disorders. CNANOM. 2019;9(3):198 [Crossref]
10- Xue S, Zhou X, Yang Z, Si X, Sun X. Stroke-induced damage on the blood–brain barrier. Front Neurol. 2023;14 [Crossref]
11- Qosa H, Volpe D. The development of biological therapies for neurological diseases: moving on from previous failures. Expert Opinion on Drug Discovery. 2018;13(4):283 [Crossref]
12- Zhou Y, Liyanage P, Devadoss D, Rios Guevara L, Cheng L, Graham R, Chand H, Al-Youbi A, Bashammakh A, El-Shahawi M, Leblanc R. Nontoxic amphiphilic carbon dots as promising drug nanocarriers across the blood–brain barrier and inhibitors of β-amyloid. Nanoscale. 2019;11(46):22387 [Crossref]
13- Korshoj L, Shi W, Duan B, Kielian T. The Prospect of Nanoparticle Systems for Modulating Immune Cell Polarization During Central Nervous System Infection. Front Immunol. 2021;12 [Crossref]
14- Vargas-Rodríguez P, Cuenca-Martagón A, Castillo-González J, Serrano-Martínez I, Luque R, Delgado M, González-Rey E. Novel Therapeutic Opportunities for Neurodegenerative Diseases with Mesenchymal Stem Cells: The Focus on Modulating the Blood-Brain Barrier. IJMS. 2023;24(18):14117 [Crossref]
15- Shaw T, Paul P. Recent Approaches and Success of Liposome-Based Nano Drug Carriers for the Treatment of Brain Tumor. CDD. 2022;19(8):815 [Crossref]
16- Hajal C, Offeddu G, Shin Y, Zhang S, Morozova O, Hickman D, Knutson C, Kamm R. Engineered human blood–brain barrier microfluidic model for vascular permeability analyses. Nat Protoc. 2022;17(1):95 [Crossref]
17- Reshma S, Megha K, Amir S, Rukhiya S, Mohanan P. Blood brain barrier-on-a-chip to model neurological diseases. Journal of Drug Delivery Science and Technology. 2023;80:104174 [Crossref]
18- Dancy C, Heintzelman K, Katt M. The Glycocalyx: The Importance of Sugar Coating the Blood-Brain Barrier. IJMS. 2024;25(15):8404 [Crossref]
19- Komorowska J, Wątroba M, Bednarzak M, Grabowska A, Szukiewicz D. Anti-Inflammatory Action of Resveratrol in the Central Nervous System in Relation to Glucose Concentration—An In Vitro Study on a Blood–Brain Barrier Model. IJMS. 2024;25(6):3110 [Crossref]
20- Li M, Shi K, Tang X, Wei J, Cun X, Chen X, Yu Q, Zhang Z, He Q. pH-sensitive folic acid and dNP2 peptide dual-modified liposome for enhanced targeted chemotherapy of glioma. European Journal of Pharmaceutical Sciences. 2018;124:240 [Crossref]
21- Huda M, Nafiujjaman M, Deaguero I, Okonkwo J, Hill M, Kim T, Nurunnabi M. Potential Use of Exosomes as Diagnostic Biomarkers and in Targeted Drug Delivery: Progress in Clinical and Preclinical Applications. ACS Biomater Sci Eng. 2021;7(6):2106 [Crossref]
22- Juhairiyah F, de Lange E. Understanding Drug Delivery to the Brain Using Liposome-Based Strategies: Studies that Provide Mechanistic Insights Are Essential. AAPS J. 2021;23(6) [Crossref]
23- de Franciscis V. Challenging cancer targets for aptamer delivery. Biochimie. 2018;145:45 [Crossref]
24- Daraban B, Popa A, Stan M. Latest Perspectives on Alzheimer’s Disease Treatment: The Role of Blood-Brain Barrier and Antioxidant-Based Drug Delivery Systems. Molecules. 2024;29(17):4056 [Crossref]
25- Naki T, Aderibigbe B. Efficacy of Polymer-Based Nanomedicine for the Treatment of Brain Cancer. Pharmaceutics. 2022;14(5):1048 [Crossref]
26- Lorenzo M, Thomas S, Kani Y, Hinckley J, Lee M, Adler J, Verbridge S, Hsu F, Robertson J, Davalos R, Rossmeisl J. Temporal Characterization of Blood–Brain Barrier Disruption with High-Frequency Electroporation. Cancers. 2019;11(12):1850 [Crossref]
27- Khan A, Yang X, Fu M, Zhai G. Recent progress of drug nanoformulations targeting to brain. Journal of Controlled Release. 2018;291:37 [Crossref]
28- Dymova M, Taskaev S, Richter V, Kuligina E. Boron neutron capture therapy: Current status and future perspectives. Cancer Communications. 2020;40(9):406 [Crossref]
29- Seo S, Choi C, Yi K, Kim S, Lee K, Choi N, Lee H, Cha S, Kim H. An engineered neurovascular unit for modeling neuroinflammation. Biofabrication. 2021;13(3):035039 [Crossref]
30- Kang J, Cho J, Ko Y. Investigation on the effect of nanoparticle size on the blood–brain tumour barrier permeability by in situ perfusion via internal carotid artery in mice. Journal of Drug Targeting. 2019;27(1):103 [Crossref]
31- Lee D, Minko T. Nanotherapeutics for Nose-to-Brain Drug Delivery: An Approach to Bypass the Blood Brain Barrier. Pharmaceutics. 2021;13(12):2049 [Crossref]
32- Safary A, Akbarzadeh Khiavi M, Mousavi R, Barar J, Rafi M. Enzyme replacement therapies: what is the best option?. Bioimpacts. 2018;8(3):153 [Crossref]
33- Fritzen L, Wienken K, Wagner L, Kurtyka M, Vogel K, Körbelin J, Weggen S, Fricker G, Pietrzik C. Truncated mini LRP1 transports cargo from luminal to basolateral side across the blood brain barrier. Fluids Barriers CNS. 2024;21(1) [Crossref]
34- Hajal C, Campisi M, Mattu C, Chiono V, Kamm R. In vitro models of molecular and nano-particle transport across the blood-brain barrier. 2018;12(4) [Crossref]
35- Bernardo-Castro S, Sousa J, Brás A, Cecília C, Rodrigues B, Almendra L, Machado C, Santo G, Silva F, Ferreira L, Santana I, Sargento-Freitas J. Pathophysiology of Blood–Brain Barrier Permeability Throughout the Different Stages of Ischemic Stroke and Its Implication on Hemorrhagic Transformation and Recovery. Front Neurol. 2020;11 [Crossref]
36- Nunes D, Loureiro J, Pereira M. Drug Delivery Systems as a Strategy to Improve the Efficacy of FDA-Approved Alzheimer’s Drugs. Pharmaceutics. 2022;14(11):2296 [Crossref]
37- Nasyrova R, Vaiman E, Repkina V, Khasanova A, Asadullin A, Shipulin G, Altynbekov K, Al-Zamil M, Petrova M, Shnayder N. Single-Nucleotide Polymorphisms as Biomarkers of Antipsychotic-Induced Akathisia: Systematic Review. Genes. 2023;14(3):616 [Crossref]
38- Zamanlu M, Farhoudi M, Eskandani M, Mahmoudi J, Barar J, Rafi M, Omidi Y. Recent advances in targeted delivery of tissue plasminogen activator for enhanced thrombolysis in ischaemic stroke. Journal of Drug Targeting. 2018;26(2):95 [Crossref]
39- Sharma R, Malviya R, Srivastava S, Ahmad I, Rab S, Uniyal P. Targeted Treatment Strategies for Mitochondria Dysfunction: Correlation with Neurological Disorders. CDT. 2024;25(10):683 [Crossref]
40- D'Souza A, Dave K, Stetler R, S. Manickam D. Targeting the blood-brain barrier for the delivery of stroke therapies. Advanced Drug Delivery Reviews. 2021;171:332 [Crossref]
41- Chaves J, Dando S, White A, Oikari L. Blood-brain barrier transporters: An overview of function, dysfunction in Alzheimer's disease and strategies for treatment. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2024;1870(2):166967 [Crossref]
42- Zhou Y, Huang Y, Yang C, Zang X, Deng H, Liu J, Zhao E, Tian T, Pan L, Xue X. The pathways and the mechanisms by which Cryptococcus enters the brain . Mycology. 2024;15(3):345 [Crossref]
43- Salatin S, Barar J, Barzegar-Jalali M, Adibkia K, Jelvehgari M. Thermosensitive in situ nanocomposite of rivastigmine hydrogen tartrate as an intranasal delivery system: Development, characterization, ex vivo permeation and cellular studies. Colloids and Surfaces B: Biointerfaces. 2017;159:629 [Crossref]
44- Sharma R, Calderon C, Vivas-Mejia P. Targeting Non-coding RNA for Glioblastoma Therapy: The Challenge of Overcomes the Blood-Brain Barrier. Front Med Technol. 2021;3 [Crossref]
45- Suchorska B, Albert N, Bauer E, Tonn J, Galldiks N. The role of amino-acid PET in the light of the new WHO classification 2016 for brain tumors. Q J Nucl Med Mol Imaging. 2018;62(3) [Crossref]
46- Trivedi J, Yasir M, Maurya R, Tripathi A. Aptamer-based Theranostics in Oncology: Design Strategies and Limitations. BIOI. 2024;5(1) [Crossref]
47- Tavares Luiz M, Delello Di Filippo L, Carolina Alves R, Sousa Araújo V, Lobato Duarte J, Maldonado Marchetti J, Chorilli M. The use of TPGS in drug delivery systems to overcome biological barriers. European Polymer Journal. 2021;142:110129 [Crossref]
48- Agiwale B, Jadhav A, Kshirsagar S, Bele M, Sonawane C, Kakad S, Ahirrao S. Liposomal Drug Delivery System as an Emerging Technique for Treatment of “Neurodegenerative Diseases”. CNANOM. 2023;13(1):17 [Crossref]
49- Isabel U, de la Riera M. Belén A, Dolores R S, Elena G. A new frontier in neuropharmacology: Recent progress in natural products research for blood–brain barrier crossing. Current Research in Biotechnology. 2024;8:100235 [Crossref]
50- Partridge B, Kani Y, Lorenzo M, Campelo S, Allen I, Hinckley J, Hsu F, Verbridge S, Robertson J, Davalos R, Rossmeisl J. High-Frequency Irreversible Electroporation (H-FIRE) Induced Blood–Brain Barrier Disruption Is Mediated by Cytoskeletal Remodeling and Changes in Tight Junction Protein Regulation. Biomedicines. 2022;10(6):1384 [Crossref]
51- Wen B, Weng X, Zhu S, Wu X, Lin X, Chen H, He Y. Carbohydrate polymer-driven nanoparticle synthesis and functionalization in the brain tumor therapy: A review. International Journal of Biological Macromolecules. 2025;285:138194 [Crossref]
52- Uwamori H, Ono Y, Yamashita T, Arai K, Sudo R. Comparison of organ-specific endothelial cells in terms of microvascular formation and endothelial barrier functions. Microvascular Research. 2019;122:60 [Crossref]
53- Hjelm L, Lindberg H, Ståhl S, Löfblom J. Affibody Molecules Intended for Receptor-Mediated Transcytosis via the Transferrin Receptor. Pharmaceuticals. 2023;16(7):956 [Crossref]
54- Esposito C, Nuzzo S, Catuogno S, Romano S, de Nigris F, de Franciscis V. STAT3 Gene Silencing by Aptamer-siRNA Chimera as Selective Therapeutic for Glioblastoma. Molecular Therapy - Nucleic Acids. 2018;10:398 [Crossref]
55- Robuck A, McCord J, Strynar M, Cantwell M, Wiley D, Lohmann R. Tissue-Specific Distribution of Legacy and Novel Per- and Polyfluoroalkyl Substances in Juvenile Seabirds. Environ Sci Technol Lett. 2021;8(6):457 [Crossref]
56- Gallo M, Defaus S, Andreu D. 1988–2018: Thirty years of drug smuggling at the nano scale. Challenges and opportunities of cell-penetrating peptides in biomedical research. Archives of Biochemistry and Biophysics. 2019;661:74 [Crossref]
57- Ihezie S, Mathew I, McBride D, Dienel A, Blackburn S, Thankamani Pandit P. Epigenetics in blood–brain barrier disruption. Fluids Barriers CNS. 2021;18(1) [Crossref]
58- Pulgar V. Transcytosis to Cross the Blood Brain Barrier, New Advancements and Challenges. Front Neurosci. 2019;12 [Crossref]
59- Tatjana V, Domitille S, Jean-Charles S. Paraquat-induced cholesterol biosynthesis proteins dysregulation in human brain microvascular endothelial cells. Sci Rep. 2021;11(1) [Crossref]
60- Kawakita S, Mandal K, Mou L, Mecwan M, Zhu Y, Li S, Sharma S, Hernandez A, Nguyen H, Maity S, de Barros N, Nakayama A, Bandaru P, Ahadian S, Kim H, Herculano R, Holler E, Jucaud V, Dokmeci M, Khademhosseini A. Organ‐On‐A‐Chip Models of the Blood–Brain Barrier: Recent Advances and Future Prospects. Small. 2022;18(39) [Crossref]
61- Bullock J, Gillette D, Smith J. Small molecule, nanoparticle and liposomal strategies for LAT1-mediated chemotherapy delivery. Results in Chemistry. 2023;6:101056 [Crossref]
62- Moscariello P, Ng D, Jansen M, Weil T, Luhmann H, Hedrich J. Brain Delivery of Multifunctional Dendrimer Protein Bioconjugates. Advanced Science. 2018;5(5) [Crossref]
63- Sun G, Lin C, Mei G, Gu J, Fan S, Liu X, Liu R, Liu X, Chen X, Zhou C, Yi X, Jin P, Chang C, Lin X. Recovery of neurosurgical high-frequency electroporation injury in the canine brain can be accelerated by 7,8-dihydroxyflavone. Biomedicine & Pharmacotherapy. 2023;160:114372 [Crossref]
64- Farooq M, Trevaskis N. TPGS Decorated Liposomes as Multifunctional Nano-Delivery Systems. Pharm Res. 2023;40(1):245 [Crossref]
65- Zhao P, Xu Y, Fan X, Li L, Li X, Arase H, Tong Q, Zhang N, An Z. Discovery and engineering of an anti-TREM2 antibody to promote amyloid plaque clearance by microglia in 5XFAD mice. mAbs. 2022;14(1) [Crossref]
66- Mukherjee S, Madamsetty V, Bhattacharya D, Roy Chowdhury S, Paul M, Mukherjee A. Recent Advancements of Nanomedicine in Neurodegenerative Disorders Theranostics. Adv Funct Materials. 2020;30(35) [Crossref]
67- Bao Y, Lu W. Targeting cerebral diseases with enhanced delivery of therapeutic proteins across the blood-brain barrier. Expert Opinion on Drug Delivery. 2023;20(12):1681 [Crossref]
68- Panda S, Singh V. The Dysregulated MAD in Mad: A Neuro-theranostic Approach Through the Induction of Autophagic Biomarkers LC3B-II and ATG. Mol Neurobiol. 2023;60(9):5214 [Crossref]
69- Ozceylan O, Sezgin-Bayindir Z. Current Overview on the Use of Nanosized Drug Delivery Systems in the Treatment of Neurodegenerative Diseases. ACS Omega. 2024;9(33):35223 [Crossref]
70- Liao J, He W, Li L, Wang J, Gong L, Zhang Q, Lin Z. Mitochondria in brain diseases: Bridging structural-mechanistic insights into precision-targeted therapies. Cell Biomaterials. 2025;1(2):100016 [Crossref]
71- Mulvihill J, Cunnane E, Ross A, Duskey J, Tosi G, Grabrucker A. Drug Delivery Across The Blood–Brain Barrier: Recent Advances in The Use of Nanocarriers. Nanomedicine (Lond). 2020;15(2):205 [Crossref]
72- Moradi F, Dashti N. Targeting neuroinflammation by intranasal delivery of nanoparticles in neurological diseases: a comprehensive review. Naunyn-Schmiedeberg's Arch Pharmacol. 2022;395(2):133 [Crossref]
73- Amiryaghoubi N, Fathi M, Barar J, Omidian H, Omidi Y. Hybrid polymer-grafted graphene scaffolds for microvascular tissue engineering and regeneration. European Polymer Journal. 2023;193:112095 [Crossref]
74- Ding L, Kshirsagar P, Agrawal P, Murry D. Crossing the Blood–Brain Barrier: Innovations in Receptor- and Transporter-Mediated Transcytosis Strategies. Pharmaceutics. 2025;17(6):706 [Crossref]
75- Safary A, Akbarzadeh Khiavi M, Omidi Y, Rafi M. Targeted enzyme delivery systems in lysosomal disorders: an innovative form of therapy for mucopolysaccharidosis. Cell Mol Life Sci. 2019;76(17):3363 [Crossref]
76- Bittar A, Bhatt N, Kayed R. Advances and considerations in AD tau-targeted immunotherapy. Neurobiology of Disease. 2020;134:104707 [Crossref]
77- Tian Y, Zheng Z, Wang X, Liu S, Gu L, Mu J, Zheng X, Li Y, Shen S. Establishment and evaluation of glucose-modified nanocomposite liposomes for the treatment of cerebral malaria. J Nanobiotechnol. 2022;20(1) [Crossref]
78- Wang F, Cao Y, Ma L, Pei H, Rausch W, Li H. Dysfunction of Cerebrovascular Endothelial Cells: Prelude to Vascular Dementia. Front Aging Neurosci. 2018;10 [Crossref]
79- Kahroba H, Davatgaran-Taghipour Y. Exosomal Nrf2: From anti-oxidant and anti-inflammation response to wound healing and tissue regeneration in aged-related diseases. Biochimie. 2020;171-172:103 [Crossref]
80- Al-Huthaifi A, Radman B, Al-Alawi A, Mahmood F, Liu T. Mechanisms and Virulence Factors of Cryptococcus neoformans Dissemination to the Central Nervous System. JoF. 2024;10(8):586 [Crossref]
81- Kerna N, Ngwu D, Pruitt K, Carsrud N, Rodriguez D, Holets H, Flores J, Chawla S, Alozie U, Azi C, McKee D, Humam A. The Morbid Impact of Environmental Toxins on the Human Nervous System: Peripheral Neuropathy Nexus with Organic Solvents, Pesticides, and Heavy Metals. ejeba. 2024;1(3):53 [Crossref]
82- Das S, Roy S, Choudhury S, Bose A, Khila S, Das D, Ghosh P, Kumar Dhaker S, Mondal S. A Critical Review of Nanosponge Based Formulation System from The perspective of Brain Targeted Drug Delivery. RJPT. 2024;:944 [Crossref]
83- Arora S, Bajaj T, Kumar J, Goyal M, Singh A, Singh C. Recent Advances in Delivery of Peptide and Protein Therapeutics to the Brain. The Journal of Pharmacology and Experimental Therapeutics. 2024;388(1):54 [Crossref]
84- Vosoughi A, Sadigh-Eteghad S, Ghorbani M, Shahmorad S, Farhoudi M, Rafi M, Omidi Y. Mathematical Models to Shed Light on Amyloid-Beta and Tau Protein Dependent Pathologies in Alzheimer’s Disease. Neuroscience. 2020;424:45 [Crossref]
85- Pawar B, Vasdev N, Gupta T, Mhatre M, More A, Anup N, Tekade R. Current Update on Transcellular Brain Drug Delivery. Pharmaceutics. 2022;14(12):2719 [Crossref]
86- Chakraverty R, Samui S, Debnath T. Targeting of Nanoparticles towards Blood–Brain Barrier with a Potential for the Treatment of Cerebrovascular Disorders: A Systematic Review (2017–2023). 2025;6(1):53 [Crossref]
87- Rattray Z, Deng G, Zhang S, Shirali A, May C, Chen X, Cuffari B, Liu J, Zou P, Rattray N, Johnson C, Dubljevic V, Campbell J, Huttner A, Baehring J, Zhou J, Hansen J. ENT2 facilitates brain endothelial cell penetration and blood-brain barrier transport by a tumor-targeting anti-DNA autoantibody. 2021;6(14) [Crossref]
88- Zhao P, Anami Y, Gao P, Fan X, Li L, Tsuchikama K, Zhang N, an Z. Enhanced anti-angiogenetic effect of transferrin receptor-mediated delivery of VEGF-trap in a glioblastoma mouse model. mAbs. 2022;14(1) [Crossref]
89- Wohlrab J, Stintzing D, Schultz L, Jügelt K, Schroeder O. Influence of Janus Kinase Inhibitors on the Neuronal Activity as a Proof-of-Concept Model for Itch. Skin Pharmacol Physiol. 2022;35(2):94 [Crossref]
90- Bukari B, Samarasinghe R, Noibanchong J, Shigdar S. Non-Invasive Delivery of Therapeutics into the Brain: The Potential of Aptamers for Targeted Delivery. Biomedicines. 2020;8(5):120 [Crossref]
91- Chernykh , Shchulkin , Pravkin , Gatsanoga , Yakusheva . Inhibition of ABCB1 activity in cerebrovascular disease may increase pharmacotherapy effectiveness . 2021;15(1) [Crossref]
92- Del Amo L, Cano A, Ettcheto M, Souto E, Espina M, Camins A, García M, Sánchez-López E. Surface Functionalization of PLGA Nanoparticles to Increase Transport across the BBB for Alzheimer’s Disease. Applied Sciences. 2021;11(9):4305 [Crossref]
93- van den Broek S, Shalgunov V, Herth M. Transport of nanomedicines across the blood-brain barrier: Challenges and opportunities for imaging and therapy. Biomaterials Advances. 2022;141:213125 [Crossref]
94- Teixeira M, Lopes C, Amaral M, Costa P. Current insights on lipid nanocarrier-assisted drug delivery in the treatment of neurodegenerative diseases. European Journal of Pharmaceutics and Biopharmaceutics. 2020;149:192 [Crossref]
95- Eshraghi M, Ahmadi M, Afshar S, Lorzadeh S, Adlimoghaddam A, Rezvani Jalal N, West R, Dastghaib S, Igder S, Torshizi S, Mahmoodzadeh A, Mokarram P, Madrakian T, Albensi B, Łos M, Ghavami S, Pecic S. Enhancing autophagy in Alzheimer's disease through drug repositioning. Pharmacology & Therapeutics. 2022;237:108171 [Crossref]
96- Seo S, Kim H, Sung J, Choi N, Lee K, Kim H. Microphysiological systems for recapitulating physiology and function of blood-brain barrier. Biomaterials. 2020;232:119732 [Crossref]
97- Levi J, Duan H, Yaghoubi S, Packiasamy J, Huynh L, Lam T, Shaikh F, Behera D, Song H, Blecha J, Jivan S, Seo Y, VanBrocklin H. Biodistribution of a Mitochondrial Metabolic Tracer, [18F]F-AraG, in Healthy Volunteers. Mol Imaging. 2022;2022 [Crossref]
98- Andjelkovic A, Stamatovic S, Phillips C, Martinez-Revollar G, Keep R. Modeling blood–brain barrier pathology in cerebrovascular disease in vitro: current and future paradigms. Fluids Barriers CNS. 2020;17(1) [Crossref]
99- Palan F, Chatterjee B. Dendrimers in the context of targeting central nervous system disorders. Journal of Drug Delivery Science and Technology. 2022;73:103474 [Crossref]
100- Kim J, Ahn S, Kim Y. Nanotherapeutics engineered to cross the blood-brain barrier for advanced drug delivery to the central nervous system. Journal of Industrial and Engineering Chemistry. 2019;73:8 [Crossref]
101- Steimle B, Smith F, Kosman D. The solute carriers ZIP8 and ZIP14 regulate manganese accumulation in brain microvascular endothelial cells and control brain manganese levels. Journal of Biological Chemistry. 2019;294(50):19197 [Crossref]
102- Sun Y, Zabihi M, Li Q, Li X, Kim B, Ubogu E, Raja S, Wesselmann U, Zhao C. Drug Permeability: From the Blood–Brain Barrier to the Peripheral Nerve Barriers. Advanced Therapeutics. 2023;6(4) [Crossref]
103- Suwanttananuruk P, Jiaranaikulwanitch J, Waiwut P, Vajragupta O. Lead discovery of a guanidinyl tryptophan derivative on amyloid cascade inhibition. 2020;18(1):546 [Crossref]
104- Constantinou C, Meliou K, Skouras A, Siafaka P, Christodoulou P. Liposomes against Alzheimer’s Disease: Current Research and Future Prospects. Biomedicines. 2024;12(7):1519 [Crossref]
105- Presset A, Bodard S, Lefèvre A, Millet A, Oujagir E, Dupuy C, Iazourène T, Bouakaz A, Emond P, Escoffre J, Nadal-Desbarats L. First Metabolomic Signature of Blood-Brain Barrier Opening Induced by Microbubble-Assisted Ultrasound. Front Mol Neurosci. 2022;15 [Crossref]
106- Zhang X, Zhou J, Gu Z, Zhang H, Gong Q, Luo K. Advances in nanomedicines for diagnosis of central nervous system disorders. Biomaterials. 2021;269:120492 [Crossref]
107- Bajracharya R, Caruso A, Vella L, Nisbet R. Current and Emerging Strategies for Enhancing Antibody Delivery to the Brain. Pharmaceutics. 2021;13(12):2014 [Crossref]
108- Nasyrova R, Shnayder N, Osipova S, Khasanova A, Efremov I, Al-Zamil M, Petrova M, Narodova E, Garganeeva N, Shipulin G. Genetic Predictors of Antipsychotic Efflux Impairment via Blood-Brain Barrier: Role of Transport Proteins. Genes. 2023;14(5):1085 [Crossref]
109- di Polidoro A, Cafarchio A, Vecchione D, Donato P, De Nola F, Torino E. Revealing Angiopep-2/LRP1 Molecular Interaction for Optimal Delivery to Glioblastoma (GBM). Molecules. 2022;27(19):6696 [Crossref]
110- Perolina E, Meissner S, Raos B, Harland B, Thakur S, Svirskis D. Translating ultrasound-mediated drug delivery technologies for CNS applications. Advanced Drug Delivery Reviews. 2024;208:115274 [Crossref]
111- Majzúnová M, Pakanová Z, Kvasnička P, Bališ P, Čačányiová S, Dovinová I. Age-dependent redox status in the brain stem of NO-deficient hypertensive rats. J Biomed Sci. 2017;24(1) [Crossref]
112- Zubkov E, Zorkina Y, Orshanskaya E, Khlebnikova N, Krupina N, Chekhonin V. Changes in Gene Expression Profiles in Adult Rat Brain Structures after Neonatal Action of Dipeptidyl Peptidase-IV Inhibitors. Neuropsychobiology. 2017;76(2):89 [Crossref]
113- Song J, Bang S, Choi N, Kim H. Brain organoid-on-a-chip: A next-generation human brain avatar for recapitulating human brain physiology and pathology. 2022;16(6) [Crossref]
114- Shabbir U, Rubab M, Tyagi A, Oh D. Curcumin and Its Derivatives as Theranostic Agents in Alzheimer’s Disease: The Implication of Nanotechnology. IJMS. 2020;22(1):196 [Crossref]
115- Gruenbaum B, Zlotnik A, Fleidervish I, Frenkel A, Boyko M. Glutamate Neurotoxicity and Destruction of the Blood–Brain Barrier: Key Pathways for the Development of Neuropsychiatric Consequences of TBI and Their Potential Treatment Strategies. IJMS. 2022;23(17):9628 [Crossref]
116- Zhang S, Gan L, Cao F, Wang H, Gong P, Ma C, Ren L, Lin Y, Lin X. The barrier and interface mechanisms of the brain barrier, and brain drug delivery. Brain Research Bulletin. 2022;190:69 [Crossref]
117- Liu M, Wang B, Yi S, Dou X, Zhang Y, Yu H, Zhang X, Dong S, Feng J, Cao Z, Zhu L. Novel insights into the mechanisms of bioaccumulation and tissue-specific distribution of hexafluoropropylene oxide homologues, novel PFOA alternatives, in zebrafish (Danio rerio). Environment International. 2024;192:109053 [Crossref]
118- Madani F, Esnaashari S, Webster T, Khosravani M, Adabi M. Polymeric nanoparticles for drug delivery in glioblastoma: State of the art and future perspectives. Journal of Controlled Release. 2022;349:649 [Crossref]
119- Vujić T, Schvartz D, Iliuk A, Sanchez J. Ubiquinone Metabolism and Transcription HIF-1 Targets Pathway Are Toxicity Signature Pathways Present in Extracellular Vesicles of Paraquat-Exposed Human Brain Microvascular Endothelial Cells. IJMS. 2021;22(10):5065 [Crossref]
120- Miyata S. Glial functions in the blood-brain communication at the circumventricular organs. Front Neurosci. 2022;16 [Crossref]
121- R. Pagar R, V. Suryawanshi M. A SYSTEMATIC OVERVIEW ON NOSE TO BRAIN DRUG DELIVERY SYSTEM IN TREATMENT OF NEURODEGENERATIVE DISORDERS. IND DRU. 2022;59(11):7 [Crossref]
122- Martín-Hernández D, Muñoz-López M, Tendilla-Beltrán H, Caso J, García-Bueno B, Menchén L, Leza J. Immune System and Brain/Intestinal Barrier Functions in Psychiatric Diseases: Is Sphingosine-1-Phosphate at the Helm?. IJMS. 2023;24(16):12634 [Crossref]
123- Giaume C, Naus C, Sáez J, Leybaert L. Glial Connexins and Pannexins in the Healthy and Diseased Brain. Physiological Reviews. 2021;101(1):93 [Crossref]
124- Kim H. Engineered models for studying blood-brain-barrier-associated brain physiology and pathology. Organoid. 2021;1:e10 [Crossref]
125- Lam F, Tsedev U, Kasper E, Belcher A. Forging the Frontiers of Image-Guided Neurosurgery—The Emerging Uses of Theranostics in Neurosurgical Oncology. Front Bioeng Biotechnol. 2022;10 [Crossref]
126- Qin M, Wang L, Wu D, Williams C, Xu D, Kranz E, Guo Q, Guan J, Vinters H, Lee Y, Xie Y, Luo Y, Sun G, Sun X, He Z, Lu Y, Kamata M, Wen J, Chen I. Enhanced Delivery of Rituximab Into Brain and Lymph Nodes Using Timed-Release Nanocapsules in Non-Human Primates. Front Immunol. 2020;10 [Crossref]
127- Jadhav S, Yenorkar N, Bondre R, Karemore M, Bali N. Nanomedicines encountering HIV dementia: A guiding star for neurotherapeutics. Journal of Drug Delivery Science and Technology. 2022;71:103315 [Crossref]
128- Omidi Y, Kianinejad N, Kwon Y, Omidian H. Drug delivery and targeting to brain tumors: considerations for crossing the blood-brain barrier. Expert Review of Clinical Pharmacology. 2021;14(3):357 [Crossref]
129- Mendes M, Sousa J, Pais A, Vitorino C. Targeted Theranostic Nanoparticles for Brain Tumor Treatment. Pharmaceutics. 2018;10(4):181 [Crossref]
130- Li C, Qian J, Chu Y. Advances in Brain Delivery Systems Based on Biomimetic Nanoparticles. ChemNanoMat. 2022;8(6) [Crossref]
131- Hu L, Wang Y, Zhang Y, Yang N, Han H, Shen Y, Cui D, Guo S. Angiopep-2 modified PEGylated 2-methoxyestradiol micelles to treat the PC12 cells with oxygen-glucose deprivation/reoxygenation. Colloids and Surfaces B: Biointerfaces. 2018;171:638 [Crossref]
132- Jojo G, Kuppusamy G. Scope of new formulation approaches in the repurposing of pioglitazone for the management of Alzheimer’s disease. J Clin Pharm Ther. 2019;44(3):337 [Crossref]
133- Lim Y, Ryu I, Jung Y, Helmlinger G, Kim I, Park H, Kang H, Lee J, Lee H, Lee K, Jang H, Ha D, Park J, Won J, Lim K, Jeon C, Cho H, Min H, Ryu J. l-Type amino acid transporter 1-targeting nanoparticles for antisense oligonucleotide delivery to the CNS. Molecular Therapy - Nucleic Acids. 2024;35(4):102340 [Crossref]
134- Chaves J, Wasielewska J, Cuní-López C, Rantanen L, Lee S, Koistinaho J, White A, Oikari L. Alzheimer's disease brain endothelial-like cells reveal differential drug transporter expression and modulation by potentially therapeutic focused ultrasound. Neurotherapeutics. 2024;21(1):e00299 [Crossref]
135- Uram Ł, Markowicz J, Misiorek M, Filipowicz-Rachwał A, Wołowiec S, Wałajtys-Rode E. Celecoxib substituted biotinylated poly(amidoamine) G3 dendrimer as potential treatment for temozolomide resistant glioma therapy and anti-nematode agent. European Journal of Pharmaceutical Sciences. 2020;152:105439 [Crossref]
136- Kato R, Zeng W, Siramshetty V, Williams J, Kabir M, Hagen N, Padilha E, Wang A, Mathé E, Xu X, Shah P. Development and validation of PAMPA-BBB QSAR model to predict brain penetration potential of novel drug candidates. Front Pharmacol. 2023;14 [Crossref]
137- Moura R, Martins C, Pinto S, Sousa F, Sarmento B. Blood-brain barrier receptors and transporters: an insight on their function and how to exploit them through nanotechnology. Expert Opinion on Drug Delivery. 2019;16(3):271 [Crossref]
138- Song P, Song N, Li L, Wu M, Lu Z, Zhao X. Angiopep-2-Modified Carboxymethyl Chitosan-Based pH/Reduction Dual-Stimuli-Responsive Nanogels for Enhanced Targeting Glioblastoma. Biomacromolecules. 2021;22(7):2921 [Crossref]
139- Yang S, Chen Z, Zhou P, Xia J, Deng T, Yu C. Carbon dots based on endogenous nutrients with visible and NIR fluorescence to penetrate blood-brain barrier. Carbon. 2023;202:130 [Crossref]
140- Dion-Albert L, Bandeira Binder L, Daigle B, Hong-Minh A, Lebel M, Menard C. Sex differences in the blood–brain barrier: Implications for mental health. Frontiers in Neuroendocrinology. 2022;65:100989 [Crossref]
141- Morris E, Daignault-Mill S, Stehbens S, Genovesi L, Lagendijk A. Addressing blood-brain-tumor-barrier heterogeneity in pediatric brain tumors with innovative preclinical models. Front Oncol. 2023;13 [Crossref]
142- Nagaraju P, S A, Priyadarshini P. Tau-aggregation inhibition: promising role of nanoencapsulated dietary molecules in the management of Alzheimer’s disease. Critical Reviews in Food Science and Nutrition. 2023;63(32):11153 [Crossref]
143- Kumar M, Sharma G, Kumar R, Singh B, Katare O, Raza K. Lysine-Based C60-Fullerene Nanoconjugates for Monomethyl Fumarate Delivery: A Novel Nanomedicine for Brain Cancer Cells. ACS Biomater Sci Eng. 2018;4(6):2134 [Crossref]
144- Yanev P, van Tilborg G, Boere K, Stowe A, van der Toorn A, Viergever M, Hennink W, Vermonden T, Dijkhuizen R. Thermosensitive Biodegradable Hydrogels for Local and Controlled Cerebral Delivery of Proteins: MRI-Based Monitoring of In Vitro and In Vivo Protein Release. ACS Biomater Sci Eng. 2023;9(2):760 [Crossref]
145- Kaya M, Ahishali B. Basic physiology of the blood-brain barrier in health and disease: a brief overview. Tissue Barriers. 2021;9(1):1840913 [Crossref]
146- Augustine R, Aqel A, Kalva S, Joshy K, Nayeem A, Hasan A. Bioengineered microfluidic blood-brain barrier models in oncology research. Translational Oncology. 2021;14(7):101087 [Crossref]
147- Hajal C, Le Roi B, Kamm R, Maoz B. Biology and Models of the Blood–Brain Barrier. Annu Rev Biomed Eng. 2021;23(1):359 [Crossref]
148- Hendy A, Hall R. Cardiac Surgery and the Blood-Brain Barrier. Anesthesiology Clinics. 2019;37(4):787 [Crossref]
149- Goshtasbi H, Pakchin P, Movafeghi A, Barar J, Castejon A, Omidian H, Omidi Y. Impacts of oxidants and antioxidants on the emergence and progression of Alzheimer's disease. Neurochemistry International. 2022;153:105268 [Crossref]
150- Furquan A, Hafeez A, Rahman M. Brain targeting of drugs via intranasal route in conjunction with nanoparticle-based systems: an updated review. J Nanopart Res. 2023;25(11) [Crossref]
151- Kirbas Cilingir E, Seven E, Zhou Y, Walters B, Mintz K, Pandey R, Wikramanayake A, Chusuei C, Vanni S, Graham R, Leblanc R. Metformin derived carbon dots: Highly biocompatible fluorescent nanomaterials as mitochondrial targeting and blood-brain barrier penetrating biomarkers. Journal of Colloid and Interface Science. 2021;592:485 [Crossref]
152- Teleanu D, Negut I, Grumezescu V, Grumezescu A, Teleanu R. Nanomaterials for Drug Delivery to the Central Nervous System. Nanomaterials. 2019;9(3):371 [Crossref]
153- Zipfel P, Rochais C, Baranger K, Rivera S, Dallemagne P. Matrix Metalloproteinases as New Targets in Alzheimer’s Disease: Opportunities and Challenges. J Med Chem. 2020;63(19):10705 [Crossref]
154- Caffrey T, Button E, Robert J. Toward three-dimensional in vitro models to study neurovascular unit functions in health and disease. Neural Regen Res. 2021;16(11):2132 [Crossref]
155- Steffens L, Morás A, Arantes P, Masterson K, Cao Z, Nugent M, Moura D. Electrospun PVA-Dacarbazine nanofibers as a novel nano brain-implant for treatment of glioblastoma: in silico and in vitro characterization. European Journal of Pharmaceutical Sciences. 2020;143:105183 [Crossref]
156- Jafari B, Pourseif M, Barar J, Rafi M, Omidi Y. Peptide-mediated drug delivery across the blood-brain barrier for targeting brain tumors. Expert Opinion on Drug Delivery. 2019;16(6):583 [Crossref]
157- Dehnbostel F, Dixit V, Preissner R, Banerjee P. Non-animal models for blood–brain barrier permeability evaluation of drug-like compounds. Sci Rep. 2024;14(1) [Crossref]
158- Teleanu D, Chircov C, Grumezescu A, Volceanov A, Teleanu R. Blood-Brain Delivery Methods Using Nanotechnology. Pharmaceutics. 2018;10(4):269 [Crossref]
159- Ali S, Ali H, Shafi M, Malik A. Breaking barriers: exploring blood–brain barrier crossing mechanisms with nanomedicine for effective glioma treatment. 3 Biotech. 2025;15(7) [Crossref]
160- Fernandez M, Nigro M, Travagli A, Pasquini S, Vincenzi F, Varani K, Borea P, Merighi S, Gessi S. Strategies for Drug Delivery into the Brain: A Review on Adenosine Receptors Modulation for Central Nervous System Diseases Therapy. Pharmaceutics. 2023;15(10):2441 [Crossref]
161- Abdelsalam M, Ahmed M, Osaid Z, Hamoudi R, Harati R. Insights into Exosome Transport through the Blood–Brain Barrier and the Potential Therapeutical Applications in Brain Diseases. Pharmaceuticals. 2023;16(4):571 [Crossref]
162- Skurlova M, Holubova K, Kleteckova L, Kozak T, Kubova H, Horacek J, Vales K. Chemobrain in blood cancers: How chemotherapeutics interfere with the brain's structure and functionality, immune system, and metabolic functions. Medicinal Research Reviews. 2024;44(1):5 [Crossref]
163- Poustforoosh A, Nematollahi M, Hashemipour H, Pardakhty A. Recent advances in Bio-conjugated nanocarriers for crossing the Blood-Brain Barrier in (pre-)clinical studies with an emphasis on vesicles. Journal of Controlled Release. 2022;343:777 [Crossref]

As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences. 
Acceptance rate (2024): 20% 
Publication fee: Free of charge

Indexing/Abstracting Info
PubMed; PubMed Central; Scopus; Science Citation Index Expanded; Google Scholar;   SJR; Essential Science Indicators; Embase; EBSCOhost; CAS: DOAJ: SHERPA/RoMEO
Member of   
Follower of ICMJE
Permission: Creative Commons